Benfotiamine

CAS Number	22457-89-2 (live-verified; multiple independent registries)
Molecular Formula / MW	C19H23N4O6PS / 466.45 g/mol
Chemical Class	Amphiphilic S-acyl thiamine derivative — benzoylthiamine monophosphate. A synthetic prodrug of thiamine
Source	Synthetic. Note: it is not a naturally occurring compound, despite frequent "allicin-derived" marketing
Typical Standardisation	Benfotiamine by HPLC; ≥98% commercial grade
Key Mechanism	Activates transketolase, diverting glycolytic intermediates into the pentose phosphate pathway — blocking hyperglycaemia-driven damage pathways
Claim Strength (Overview)	Moderate for symptomatic diabetic polyneuropathy (BEDIP and BENDIP RCTs); Emerging elsewhere
Buy from Herbuno	Benfotiamine Powder →

Name origin: Benfotiamine is a contraction of benzoyl and thiamine — it is S-benzoylthiamine O-monophosphate, an amphiphilic S-acyl derivative of vitamin B1. The "amphiphilic" descriptor is the whole point: thiamine itself is water-soluble and its intestinal absorption is saturable and rate-limited, whereas benfotiamine’s lipophilic benzoyl group allows passive diffusion across membranes, producing markedly higher thiamine bioavailability. A correction worth making: benfotiamine is frequently marketed as "derived from garlic" or as an allithiamine. This is misleading. Benfotiamine is a synthetic compound. The allithiamines (such as allicin-thiamine adducts) are a related family discovered in garlic research, but benfotiamine itself is not a natural product and does not occur in garlic. Traditional use: None, and none should be claimed. Benfotiamine was developed in Japan in the 1950s as part of a programme to create better-absorbed thiamine derivatives, and has been used clinically in Germany and elsewhere for decades. Research trajectory: Benfotiamine research has been unusually mechanism-driven, focused on the four hyperglycaemia-induced damage pathways (polyol, hexosamine, PKC, and AGE formation) and on transketolase as a means of shunting flux away from all of them.

---

Evidence for Benfotiamine Applications

The human trial evidence in diabetic neuropathy is genuine and reasonably specific. A three-week randomized controlled pilot study (the BEDIP study) enrolled forty inpatients aged 18–70 with type 1 or type 2 diabetes and polyneuropathy of no longer than two years’ duration; twenty received two 50 mg benfotiamine tablets four times daily and twenty received placebo, and the investigation concluded that it had confirmed the results of two earlier randomized controlled trials and provided further evidence for beneficial effects of benfotiamine in patients with diabetic neuropathy (Haupt 2005). The larger BENDIP study subsequently found a reduction in neuropathic symptoms after six weeks at 300 mg twice daily, identifying that as the optimal effective and safe dose. Claim strength: Moderate.

The mechanism is specific and mechanistically elegant rather than a generic antioxidant story, and it is worth understanding because it explains the indication. Benfotiamine is a fat-soluble thiamine homolog shown to block three major pathways of hyperglycaemia-induced microvascular damage (Balakumar 2010). It does this by activating transketolase, a thiamine-dependent enzyme that diverts glyceraldehyde-3-phosphate and fructose-6-phosphate — the upstream substrates feeding the polyol, hexosamine, PKC, and AGE-formation pathways — into the non-oxidative pentose phosphate pathway. Cut the substrate supply and all four damage pathways are throttled simultaneously. Claim strength: Moderate (mechanistic).

The bioavailability advantage over plain thiamine is the entire commercial rationale and is well established. Thiamine absorption is via a saturable active-transport mechanism that limits uptake at higher doses; benfotiamine’s lipophilic character permits passive diffusion, producing substantially higher plasma and tissue thiamine levels than equivalent doses of thiamine hydrochloride. This is a real, measurable pharmacokinetic advantage — and it is worth noting that it is one of the relatively few "enhanced bioavailability" claims in the supplement market that is actually well supported. Claim strength: High.

The anti-AGE activity is documented in vitro and in vivo. Benfotiamine has been shown to correct defective replication of, and prevent formation of advanced glycation end products in, human umbilical vein endothelial cells grown under high-glucose conditions; in vivo, it increases nerve conduction velocity and prevents microalbuminuria, proteinuria, and AGE formation in mice with streptozotocin-induced diabetes. This is coherent with the transketolase mechanism and with the neuropathy indication, and it is the reason benfotiamine appears alongside carnosine and alpha-lipoic acid in the anti-glycation literature. Claim strength: Moderate (preclinical).

The broader claims deserve a more sceptical hearing than they usually get. Preclinical work has reported that benfotiamine reduces amyloid plaques and phosphorylated tau in a transgenic Alzheimer’s mouse model and improves Morris water maze performance, attenuates inflammatory response in LPS-stimulated microglia, and reduces markers of hepatic damage in a rat model of acute ethanol intoxication. A preliminary human evaluation in amnestic mild cognitive impairment and mild Alzheimer’s disease has been conducted. These are interesting and genuinely worth watching — and they are preliminary, and should not be used to support consumer claims. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries Benfotiamine Powder. Buyers should note that benfotiamine is a synthetic S-acyl thiamine derivative, not a naturally occurring compound — the frequent "derived from garlic" or "allithiamine" positioning in the market is misleading, and Herbuno will not support that framing.

Clinical dosing in the diabetic neuropathy trials has been well defined: the BEDIP pilot used 400 mg/day (two 50 mg tablets four times daily) over three weeks, while the larger BENDIP study used 300 mg twice daily (600 mg/day) over six weeks and identified that as the optimal effective and safe dose. Benefit emerged over weeks rather than days. Benfotiamine is fat-soluble and absorption is improved when taken with food. Formulators should note that these are pharmacological rather than nutritional doses — the RDA for thiamine is roughly 1–1.5 mg — and should be clear which of those two propositions their product is making.

Analytical verification should specify benfotiamine by HPLC (≥98%) against a certified reference standard, with related substances quantified — free thiamine, S-benzoylthiamine, and phosphorylation-state variants are the relevant impurities and their profile is a function of the synthetic route. Residual solvent testing is standard. Because benfotiamine is a phosphate ester, hydrolytic stability matters: moisture control in storage and packaging should be specified, and stability across the intended shelf life is a reasonable requirement rather than an unusual one.

Benfotiamine is well tolerated, with an extensive clinical exposure in Germany and elsewhere; the trial literature reports it as safe, and thiamine derivatives generally have a wide safety margin with no established upper limit for thiamine itself owing to renal clearance of excess. Two notes deserve statement. First, benfotiamine is used disproportionately by people with diabetes, and it is not a substitute for glycaemic control or for proper medical management of diabetic complications; positioning it in a way that might displace either would be irresponsible. Second, the broader claims — Alzheimer’s disease, hepatoprotection, anti-inflammatory activity — rest on preclinical and preliminary work and should not be presented to consumers as established, however tempting the mechanistic story.

---

Frequently Asked Questions — Benfotiamine

Is benfotiamine natural or derived from garlic?
Neither, and the market gets this wrong routinely. Benfotiamine is a synthetic S-acyl thiamine derivative — S-benzoylthiamine O-monophosphate — developed in Japan in the 1950s. The allithiamines are a related family discovered in garlic research, but benfotiamine itself does not occur in garlic and is not a natural product.

How does benfotiamine work?
Through transketolase, and the mechanism is elegant. It activates this thiamine-dependent enzyme, which diverts glyceraldehyde-3-phosphate and fructose-6-phosphate — the upstream substrates feeding the polyol, hexosamine, PKC, and AGE-formation pathways — into the pentose phosphate pathway. Cut the substrate supply and all four hyperglycaemia damage pathways are throttled at once.

Is benfotiamine really better absorbed than thiamine?
Yes, and this is one of the relatively few "enhanced bioavailability" claims in the supplement market that is genuinely well supported. Thiamine absorption uses a saturable active-transport mechanism that limits uptake at higher doses. Benfotiamine's lipophilic character permits passive diffusion, producing substantially higher plasma and tissue thiamine levels.

What dose was used in the neuropathy trials?
The BEDIP pilot used 400 mg/day over three weeks. The larger BENDIP study used 300 mg twice daily (600 mg/day) over six weeks and identified that as the optimal effective and safe dose. Benefit emerged over weeks, not days. Note these are pharmacological doses — the thiamine RDA is around 1-1.5 mg.

Related compounds: Alpha-Lipoic Acid, L-Carnosine, Berberine, L-Glutathione

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery